Veru Inc Stock Discussion

$Veru Inc (VERU.US)$
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, f...

$Veru Inc (VERU.US)$ Veru Inc: Topline Data for Primary Endpoint of Lean Body Mass Expected January 2025

$Veru Inc (VERU.US)$ Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients

$Veru Inc (VERU.US)$ what happen ? bad news ?

$Veru Inc (VERU.US)$  376 000 share acquire by STEINER MITCHELL SHUSTER
and 102 000 share to FISCH HARRY

$Veru Inc (VERU.US)$
Veru Reports Fiscal 2024 Second Quarter Financial Results and
Progress of its Enobosarm High Quality Weight Loss Clinical Program
—Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for highquality weight loss is actively enrolling—
—Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDswith significant relevant medical, clinical and scientific expertise—
—Company to present this month at upcoming American Ass...

$Veru Inc (VERU.US)$ hmm well bout ⏲️ ⏳️

$Veru Inc (VERU.US)$ another rally for veru

$Veru Inc (VERU.US)$
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has been invited to give a presentation at the GLP-1 Based Therapeutics Summit, taking place May 15-16, 2024, in Philadelphia, PA.
Presentation details:
Advanc...